Development asset linked to Kymera Therapeutics in public FDA and regional records.
biotech · Atopic Dermatitis · Moderate to Severe Atopic Dermatitis · KYMR
Kymera Therapeutics
Kymera Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
500 North Beacon Street, 4th Floor, Watertown, MA 02472, US HQ
2016 Founded
289 Employees
Public company Type
KYMR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 500 North Beacon Street, 4th Floor, Watertown, MA 02472, US
- Founded
- 2016
- Employees
- 289
- Programs
- 12
- Drugs
- 6
- Patents
- 29
Kymera Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kymera Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Kymera Therapeutics in public FDA and regional records.
-
Development asset linked to Kymera Therapeutics in public FDA and regional records.
-
Development asset linked to Kymera Therapeutics in public FDA and regional records.
-
Development asset linked to Kymera Therapeutics in public FDA and regional records.
-
Development asset linked to Kymera Therapeutics in public FDA and regional records.